|1.||Mauri, Laura: 13 articles (10/2014 - 12/2006)|
|2.||Leon, Martin B: 12 articles (12/2013 - 12/2006)|
|3.||Fitzgerald, Peter J: 11 articles (05/2012 - 08/2006)|
|4.||Jeong, Myung Ho: 10 articles (11/2015 - 03/2010)|
|5.||Kandzari, David E: 10 articles (12/2013 - 12/2006)|
|6.||Windecker, Stephan: 9 articles (10/2015 - 08/2009)|
|7.||Popma, Jeffrey J: 9 articles (12/2012 - 08/2006)|
|8.||Wijns, William: 8 articles (10/2014 - 08/2006)|
|9.||Cutlip, Donald E: 8 articles (12/2013 - 10/2008)|
|10.||Hur, Seung Ho: 7 articles (11/2015 - 03/2010)|
|1.||Coronary Artery Disease (Coronary Atherosclerosis)
04/01/2009 - "Zotarolimus for the treatment of coronary artery disease: pathophysiology, DES design, clinical evaluation and future perspective."
08/01/2012 - "To report the safety and efficacy of zotarolimus eluting stents for treatment of unprotected left main coronary artery disease. "
01/01/2013 - "Comparative efficacy of 2 zotarolimus-eluting stent generations: resolute versus endeavor stents in patients with coronary artery disease."
09/01/2014 - "Optimal duration of dual antiplatelet therapy following treatment with the endeavor zotarolimus-eluting stent in real-world Japanese patients with coronary artery disease (OPERA): study design and rationale."
04/01/2013 - "The aim of this study was to describe the process to obtain Food and Drug Administration (FDA) approval for the expanded indication for treatment with the Resolute zotarolimus-eluting stent (R-ZES) (Medtronic, Inc., Santa Rosa, California) in patients with coronary artery disease and diabetes. "
01/01/2008 - "Zotarolimus-eluting stent is associated with a significantly greater amount of neointimal hyperplasia compared with SES. "
03/01/2004 - "Given these pharmacodynamics, ABT-578 was considered beneficial for intracoronary delivery to arrest the process responsible for neointimal hyperplasia after angioplasty and stenting. "
10/01/2011 - "The purpose of this study was to test the hypothesis that an angioplasty balloon coated with the mTOR inhibitor zotarolimus (ZCB) would inhibit neointimal hyperplasia in a novel injury-based superficial femoral artery model in the familial hypercholesterolemic swine. "
03/01/2011 - "This optical coherence tomography study found relatively constant neointimal hyperplasia thickness, regardless of the zotarolimus-eluting stent length or diameter. "
09/01/2007 - "In this study, an independent correlation was observed between the CRP level before zotarolimus-eluting stent implantation and the neointimal hyperplasia volume at 4-month follow-up."
12/01/2011 - "Three-year clinical outcome with the Endeavor™ zotarolimus-eluting stent in primary percutaneous coronary intervention for ST elevation myocardial infarction: the Endeavor™ primary PCI study (E-PPCI)."
06/01/2010 - "Using optical coherence tomography, we assessed the proportion of uncovered struts at 6-month follow-up in zotarolimus-eluting stents (ZES), specifically Endeavor (Medtronic CardioVascular, Santa Rosa, California) stents, and identical bare-metal stents (BMS) implanted in patients with ST-segment elevation myocardial infarction (STEMI). "
06/05/2013 - "Comparison between zotarolimus-eluting stents and first generation drug-eluting stents in the treatment of patients with acute ST-segment elevation myocardial infarction."
04/26/2011 - "In the main analysis cohort (2.5- to 3.5-mm stents and single-lesion treatment), the primary endpoint was 12-month target lesion failure (TLF) defined as the composite of cardiac death, myocardial infarction (MI), and clinically-driven target lesion revascularization (TLR), compared with data from Endeavor zotarolimus-eluting stent (E-ZES) trials, adjusting for baseline covariates through propensity scores. "
10/09/2013 - "Long-term outcomes of patients receiving zotarolimus-eluting stents in ST elevation myocardial infarction, non-ST elevation acute coronary syndrome, and stable angina: data from the Resolute program."
10/01/2011 - "Early clinical trials with the Endeavor zotarolimus eluting stent (ZES) in western populations demonstrated low rates of target lesion revascularization with a favorable safety profile including low late stent thrombosis with up to 5 years of follow-up. "
08/01/2014 - "Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation."
05/12/2014 - "In contrast, the second-generation zotarolimus-eluting stents (ZES) were associated with increased rates of stent thrombosis and risk of target lesion revascularization in comparison with the SES (both p < 0.05) or the overall first-generation DES (both p < 0.05). "
08/01/2013 - "There was a 74% probability that EES had the lowest rate of any stent thrombosis when compared with all other stent types (no data on zotarolimus-eluting stent resolute). "
03/27/2010 - "In low-risk patients, the zotarolimus-eluting stent has been shown to reduce rates of restenosis without increasing the risk of stent thrombosis. "
11/01/2012 - "Inflammation and impaired wound healing after zotarolimus-eluting stent implantation."
01/01/2012 - "Future pathologic studies should address the long-term safety of newer generation DES including zotarolimus- and everolimus-eluting stents in terms of the improvement in reendothelialization, decreased inflammation and fibrin deposition as well as a lower incidence of stent fracture-related adverse events, and reduced neoatherosclerosis, which likely contribute to the decreased risk of LST/VLST and better patient outcomes."
|8.||glucuronyl glucosamine glycan sulfate (Vessel)
|2.||Angioplasty (Angioplasty, Transluminal)